HER2 inhibitor

September 21, 2020September 21, 2020

Phase 1 Trial Begins Dosing Patients With Investigational Brain-penetrant HER2 Inhibitor

News

Patient dosing has begun in Zion Pharma‘s Phase 1 clinical trial in the United States to evaluate the safety of its investigational HER2 inhibitor, ZN-A-1041, in people with HER2-positive breast ... Read more

January 18, 2017January 18, 2017

Investigational Therapy, Tucatinib, Shows Early Promise for HER2-positive Patients

News

Findings from a Phase 1 clinical trial show that women with heavily treated breast cancer could benefit from the investigational HER2 small molecule inhibitor tucatinib. Despite a median of five ... Read more